Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial-Reference-Cited by-同舟云学术

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

Published:2015-07 Issue:7 Volume:15 Page:785-792
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Arribas José R,Girard Pierre-Marie,Landman Roland,Pich Judit,Mallolas Josep,Martínez-Rebollar María,Zamora Francisco X,Estrada Vicente,Crespo Manuel,Podzamczer Daniel,Portilla Joaquín,Dronda Fernando,Iribarren José A,Domingo Pere,Pulido Federico,Montero Marta,Knobel Hernando,Cabié André,Weiss Laurence,Gatell José M

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference17 articles.

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,2015

2. Antiretroviral treatment of adult HIV infection;Günthard;JAMA,2014

3. Guidelines. Version 7.1. November 2014,2014

4. Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 14: 572–80.

5. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial;Raffi;Lancet,2014

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THERAPEUTIC STRATEGIES AND USE OF LOPINAVIR/RITONAVIR IN PATIENTS WITH HIGHLY RESISTANT HUMAN IMMUNODEFICIENCY VIRUS;FARMACIA;2024

2. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three‐drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study;Journal of Medical Virology;2023-10

3. Two-drug antiretroviral regimens for HIV;BMJ;2023-09-01

4. Efficacy and safety of switching lamivudine-based dual therapies for the maintenance of virologic suppression in adults with HIV-1: a systematic review and network meta-analysis;2023-08-17

5. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial;eClinicalMedicine;2023-06